Cagrilintide & semaglutide is a not-yet-approved medication pairing two long-acting copies of natural appetite hormones in one weekly injection, used for weight loss. It produces some of the largest weight losses of any medicine, plus better blood sugar and lower blood pressure. Heart, kidney and survival benefits are shown only for semaglutide alone, and lean, healthy adults are unstudied. Digestive side effects are common, and weight returns when treatment stops. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Body weight and waist circumference | No established target; track percent change from own baseline | Expected to change; trial endpoint |
| Blood pressure | Not specified in the ER | Expected to improve |
| HbA1c | 4.0–5.6% | Expected to change |
| Fasting glucose | 70–99 mg/dL | Expected to change; safety if on insulin or sulfonylureas |
| LDL cholesterol | No established target; track change from own baseline | Expected to change |
| Creatinine with eGFR | Creatinine about 0.6–1.3 mg/dL | Safety check |
| ALT | About 7–56 U/L | Expected to change (fatty liver); safety |
| GGT | Not specified in the ER | Paired with ALT; liver or bile-duct stress |
| Lipase | Within laboratory reference range | Safety check, only with persistent abdominal pain |
| TSH | About 0.4–4.0 mIU/L | Safety check if on levothyroxine |
| Lean mass by DXA | No established target; track change from own baseline | Expected to change |
| Resting heart rate | 60–100 beats per minute | Safety check |
Cadence: Baseline before starting (dilated eye exam for those with diabetes; DXA scan); weight, blood pressure, heart rate and symptoms every 4 weeks during the 16-week escalation; labs at 3 months; then every 6–12 months once the maintenance dose is stable; repeat body-composition scan at 6–12 months